EUCTR2021-005481-18-ES进行中（未招募）1 期
First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- BioNTech SE
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For both parts:
- •Histological or cytological documentation of a solid tumor that is metastatic or unresectable via a pathology report.
- •CLDN6-positive tumor sample as assessed by central testing using a validated IHC assay in formalin-fixed paraffin-embedded (FFPE) neoplastic tissues. FFPE tissue can be derived from fresh biopsies and archival samples. If archival tissue samples from several points of time are available, the most recent one is preferred.
- •Measurable disease per RECIST 1.1 (measurable per RECIST 1.1 or evaluable per GCIG criteria for ovarian tumors).
- •For Part 1 (Dose escalation):
- •Patients with advanced/metastatic ovarian, non-squamous NSCLC, endometrial, or testicular cancer, for whom there is no available standard therapy likely to confer clinical benefit, or the patient is not a candidate for such available therapy, or patients with NOS tumors not included in the eligible tumor types, including rare tumors and cancers of unknown primary, upon approval by the medical monitor. Patients must have received all available standard therapies, including targeted therapies based on mutation status (per guidelines from the FDA, ASCO, ESMO or local guidelines used at the site), and failed at least first line SOC therapy prior to enrollment.
- •For Part 2 (Expansion):
- •Expansion Cohort 1: CLDN6-positive ovarian cancer patients who have received at least one systemic treatment regimen for advanced/metastatic disease with radiographic disease progression on or after last prior treatment and who are not eligible for SOC therapy at the discretion of the investigator.
- •Expansion Cohort 2: CLDN6-positive non-squamous NSCLC who have received at least one prior systemic treatment regimen for advanced/metastatic disease with radiographic disease progression on or after last prior treatment and who are not eligible for SOC therapy at the discretion of the investigator.
- •Expansion Cohort 3: CLDN6-positive testicular cancer patients who have received at least one systemic treatment regimen for advanced/metastatic disease with radiographic disease progression on or after last prior treatment and who are not eligible for SOC therapy at the discretion of the investigator.
- •Note: Patients are considered as not eligible for SOC therapy if in the opinion of the investigator, e.g., there is no effective SOC therapy available, SOC is contraindicated or patient has refused SOC treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 86
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 130
排除标准
- •Patients who meet any of the following exclusion criteria will not be eligible for trial entry:
- •Radiotherapy, chemotherapy, or molecularly-targeted agents within 3 weeks or 5 half-lives (whichever is longer) of the start of trial treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of trial treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of trial treatment.
- •Concurrent systemic (oral or intravenous [IV]) steroid therapy >10 mg prednisone daily or its equivalent for an underlying condition apart from physiologic corticosteroid replacement therapy.
- •Major surgery within 4 weeks before the first dose of BNT142.
- •Ongoing or active infection requiring IV treatment with anti-infective therapy that has been administered less than 2 weeks prior to the first dose of BNT142.
- •Prior treatment with a CLDN6 targeting monoclonal antibody.
- •Side effects of any prior therapy or procedures for any medical condition not recovered to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5 Grade =1, with the exception of alopecia, anorexia, vitiligo, fatigue, hyperthyroidism, hypothyroidism, and peripheral neuropathy. Anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy must have recovered to Grade =2. Alopecia of any grade is allowed.
- •Current evidence of new or growing brain or leptomeningeal metastases during screening. Patients with known brain metastases may be eligible if they:
- •- Had radiotherapy, surgery or stereotactic surgery for the brain metastases;
- •- Have no neurological symptoms (excluding Grade =2 neuropathy);
- •- Have stable brain metastasis on the computer tomography (CT) or magnetic resonance imaging (MRI) scan within 4 weeks before signing the informed consent form (ICF); and
- •- Are not undergoing acute corticosteroid therapy or steroid taper.
- •Notes: Patients with central nervous system (CNS) symptoms should undergo a CT scan or MRI of the brain to exclude new or progressive brain metastases. Spinal bone metastases are allowed, unless imminent fracture with cord compression is anticipated.
- •Pregnant or breastfeeding or planning to get pregnant within 6 months of the last dose of BNT142.
研究者
相似试验
招募中
1 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancerSolid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065143Term: Malignant solid tumour Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10043302Term: Testicular cancer Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10007460Term: Carcinoma of unknown primary Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2024-512639-58-00BioNTech SE330
尚未招募
2 期
First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumorstumors10027655cancerNL-OMON53910BioNTech SE14
招募中
不适用
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
已完成
不适用
A phase 1, first-in-human, multicenter, open-label, dose-escalation study to characterize the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumorsNL-OMON51895Molecular Partners AG30
尚未招募
1 期
A Safety and Tolerability Study Evaluating CTX320 in Subjects With Elevated Lipoprotein(a) and a History of Atherosclerotic Cardiovascular Disease or Calcific Aortic Valve Stenosis.Cardiovascular - Other cardiovascular diseasesElevated Lipoprotein(a)Calcific Aortic Valve StenosisAtherosclerotic Cardiovascular DiseaseMetabolic and Endocrine - Other metabolic disordersACTRN12623001095651CRISPR Therapeutics AG24